Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 1
1991 1
1992 1
1993 3
1996 1
2001 1
2005 1
2006 2
2007 1
2008 1
2010 1
2013 1
2014 3
2015 6
2016 6
2017 8
2018 8
2019 8
2020 9
2021 7
2022 8
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Molecular Characterization of Advanced-Stage Melanomas in Clinical Practice Using a Laboratory-Developed Next-Generation Sequencing Panel.
Maloberti T, De Leo A, Coluccelli S, Sanza V, Gruppioni E, Altimari A, Comito F, Melotti B, Marchese PV, Dika E, Venturi F, Corti B, Ciccimarra G, Ciceu CA, Tallini G, de Biase D. Maloberti T, et al. Among authors: melotti b. Diagnostics (Basel). 2024 Apr 11;14(8):800. doi: 10.3390/diagnostics14080800. Diagnostics (Basel). 2024. PMID: 38667446 Free PMC article.
Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program.
Quaglino P, Ascierto PA, Consoli F, Queirolo P, Spagnolo F, Morelli MF, Berardi R, Chiarion-Sileni V, Tucci M, Troiani T, Melotti B, Rossi E, Mandala M, Rinaldi G, Marcon IG, Pizzuti M, Del Vecchio M. Quaglino P, et al. Among authors: melotti b. Cancer Manag Res. 2023 Nov 11;15:1271-1281. doi: 10.2147/CMAR.S423970. eCollection 2023. Cancer Manag Res. 2023. PMID: 38027240 Free PMC article.
Analysis of basal cell carcinomas' histological subtypes and relative response to vismodegib in six patients diagnosed with Gorlin-Goltz syndrome: A retrospective study.
Scotti B, Melotti B, Baraldi C, Comito F, Venturi F, Lambertini M, Dika E. Scotti B, et al. Among authors: melotti b. J Eur Acad Dermatol Venereol. 2024 Apr;38(4):e339-e341. doi: 10.1111/jdv.19608. Epub 2023 Nov 10. J Eur Acad Dermatol Venereol. 2024. PMID: 37909360 No abstract available.
Cemiplimab-Induced Alopecia Areata.
Piraccini BM, Comito F, Melotti B, Stanganelli I, Medri M, Savoia F. Piraccini BM, et al. Among authors: melotti b. Int J Trichology. 2023 Mar-Apr;15(2):77-78. doi: 10.4103/ijt.ijt_107_21. Epub 2023 Jul 28. Int J Trichology. 2023. PMID: 37701555 Free PMC article. No abstract available.
Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience.
Merli M, Accorinti M, Romagnuolo M, Marzano A, Di Zenzo G, Moro F, Antiga E, Maglie R, Cozzani E, Parodi A, Gasparini G, Sollena P, De Simone C, Caproni M, Pisano L, Fattore D, Balestri R, Sena P, Vezzoli P, Teoli M, Ardigò M, Vassallo C, Michelerio A, Satta RR, Dika E, Melotti B, Ribero S, Quaglino P. Merli M, et al. Among authors: melotti b. Front Med (Lausanne). 2023 Jul 20;10:1208418. doi: 10.3389/fmed.2023.1208418. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37547602 Free PMC article.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.
John T, Grohé C, Goldman JW, Shepherd FA, de Marinis F, Kato T, Wang Q, Su WC, Choi JH, Sriuranpong V, Melotti B, Fidler MJ, Chen J, Albayaty M, Stachowiak M, Taggart S, Wu YL, Tsuboi M, Herbst RS, Majem M. John T, et al. Among authors: melotti b. J Thorac Oncol. 2023 Sep;18(9):1209-1221. doi: 10.1016/j.jtho.2023.05.015. Epub 2023 May 24. J Thorac Oncol. 2023. PMID: 37236398 Free article. Clinical Trial.
83 results